Cargando…

Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia

BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreto, Talita Lemos Neves, de Carvalho Filho, Roberto José, Shigueoka, David Carlos, Fonseca, Fernando Luiz Affonso, Ferreira, Ariel Cordeiro, Kochi, Cristiane, Aranda, Carolina Sanchez, Sarni, Roseli Oselka Saccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161655/
https://www.ncbi.nlm.nih.gov/pubmed/37147676
http://dx.doi.org/10.1186/s13023-023-02720-7
_version_ 1785037538450210816
author Barreto, Talita Lemos Neves
de Carvalho Filho, Roberto José
Shigueoka, David Carlos
Fonseca, Fernando Luiz Affonso
Ferreira, Ariel Cordeiro
Kochi, Cristiane
Aranda, Carolina Sanchez
Sarni, Roseli Oselka Saccardo
author_facet Barreto, Talita Lemos Neves
de Carvalho Filho, Roberto José
Shigueoka, David Carlos
Fonseca, Fernando Luiz Affonso
Ferreira, Ariel Cordeiro
Kochi, Cristiane
Aranda, Carolina Sanchez
Sarni, Roseli Oselka Saccardo
author_sort Barreto, Talita Lemos Neves
collection PubMed
description BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. METHODS: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan(®) were performed. RESULTS: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). CONCLUSIONS: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02720-7.
format Online
Article
Text
id pubmed-10161655
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101616552023-05-06 Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia Barreto, Talita Lemos Neves de Carvalho Filho, Roberto José Shigueoka, David Carlos Fonseca, Fernando Luiz Affonso Ferreira, Ariel Cordeiro Kochi, Cristiane Aranda, Carolina Sanchez Sarni, Roseli Oselka Saccardo Orphanet J Rare Dis Research BACKGROUND: Ataxia-telangiectasia (A-T) is a DNA repair disorder characterized by changes in several organs and systems. Advances in clinical protocols have resulted in increased survival of A-T patients, however disease progression is evident, mainly through metabolic and liver changes. OBJECTIVE: To identify the frequency of significant hepatic fibrosis in A-T patients and to verify the association with metabolic alterations and degree of ataxia. METHODS: This is a cross-sectional study that included 25 A-T patients aged 5 to 31 years. Anthropometric data, liver, inflammatory, lipid metabolism and glucose biomarkers (oral glucose tolerance test with insulin curve—OGTT) were collected. The Cooperative Ataxia Rating Scale was applied to assess the degree of ataxia. The following were calculated: Homeostasis Model Assessment—Insulin Resistance, Homeostasis Model Assessment—Adiponectin (HOMA-AD), Matsuda index, aspartate aminotransferase (AST): platelet ratio index, nonalcoholic fatty liver disease fibrosis score and BARD score. Liver ultrasonography and transient liver elastography by FibroScan(®) were performed. RESULTS: Significant hepatic fibrosis was observed in 5/25 (20%). Patients in the group with significant hepatic fibrosis were older (p < 0.001), had lower platelet count values (p = 0.027), serum albumin (p = 0.019), HDL-c (p = 0.013) and Matsuda index (p = 0.044); and high values of LDL-c (p = 0.049), AST (p = 0.001), alanine aminotransferase (p = 0.002), gamma-glutamyl transferase (p = 0.001), ferritin (p = 0.001), 120-min glycemia by OGTT (p = 0.049), HOMA-AD (p = 0.016) and degree of ataxia (p = 0.009). CONCLUSIONS: A non-invasive diagnosis of significant hepatic fibrosis was observed in 20% of A-T patients associated with changes in liver enzymes, ferritin, increased HOMA-AD, and the severity of ataxia in comparison with patients without hepatic fibrosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-023-02720-7. BioMed Central 2023-05-05 /pmc/articles/PMC10161655/ /pubmed/37147676 http://dx.doi.org/10.1186/s13023-023-02720-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Barreto, Talita Lemos Neves
de Carvalho Filho, Roberto José
Shigueoka, David Carlos
Fonseca, Fernando Luiz Affonso
Ferreira, Ariel Cordeiro
Kochi, Cristiane
Aranda, Carolina Sanchez
Sarni, Roseli Oselka Saccardo
Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title_full Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title_fullStr Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title_full_unstemmed Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title_short Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia
title_sort hepatic fibrosis: a manifestation of the liver disease evolution in patients with ataxia-telangiectasia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161655/
https://www.ncbi.nlm.nih.gov/pubmed/37147676
http://dx.doi.org/10.1186/s13023-023-02720-7
work_keys_str_mv AT barretotalitalemosneves hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT decarvalhofilhorobertojose hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT shigueokadavidcarlos hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT fonsecafernandoluizaffonso hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT ferreiraarielcordeiro hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT kochicristiane hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT arandacarolinasanchez hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia
AT sarniroselioselkasaccardo hepaticfibrosisamanifestationoftheliverdiseaseevolutioninpatientswithataxiatelangiectasia